BridgeBio is a biopharmaceutical company founded to discover, create, test and deliver transformative medicines to treat patients who suffer from genetic diseases and cancers with clear genetic drivers. BridgeBio’s pipeline of over 30 development programs ranges from early science to advanced clinical trials and its commercial organization is focused on delivering the company’s first two approved therapies. BridgeBio was founded in 2015 and its team of experienced drug discoverers, developers and innovators are committed to applying advances in genetic medicine to help patients as quickly as possible.
Eidos, a BridgeBio company, is a clinical stage biopharmaceutical company focused on addressing the large and growing unmet need caused by transthyretin amyloidosis. The company’s investigational product candidate, acoramidis, is an orally-administered small molecule designed to stabilize TTR and prevent the formation of disease-causing amyloid.
For more information visit bridgebio.com or eidostx.com.